The therapeutic potential of CBP specific inhibitors has been reported 71, 72; here, our finding further highlights the prospect of CBP inhibitors in cancer therapy, especially in cancers highly expressing DOT1L/CBP. The gene discussed is DOT1L; the disease is cancer.